|
Market Closed -
Nasdaq
00:00:00 27/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 76.99 USD | +0.03% |
|
+0.09% | +182.32% |
| 08-27 | Argenx SE completed the acquisition of Forte Biosciences, Inc.. | CI |
| 08-27 | Argenx Completes Acquisition of Forte Biosciences | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Net Income | -21.71M | -13.88M | -31.48M | -35.48M | -69.38M | |||
D&A | 36K | - | 9K | 39K | 64K | |||
Operating Income | -21.49M | -13.9M | -32.49M | -36.6M | -70.66M | |||
EBT | -21.71M | -13.88M | -31.48M | -35.48M | -68.34M | |||
CAPEX | - | - | -88K | -37K | -116K | |||
Income Tax Expense | - | - | - | - | 1.04M | |||
Interest Expense | - | - | - | - | - | |||
Total Assets | 43.31M | 42M | 38.98M | 61.56M | 82.78M |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Operating Income | -21.49M | -13.9M | -32.49M | -36.6M | -70.66M | |||
Net Income | -21.71M | -13.88M | -31.48M | -35.48M | -69.38M | |||
EBT | -21.71M | -13.88M | -31.48M | -35.48M | -68.34M | |||
CAPEX | - | - | -88K | -37K | -116K | |||
D&A | 36K | - | 9K | 39K | 64K | |||
Income Tax Expense | - | - | - | - | 1.04M | |||
Interest Expense | - | - | - | - | - | |||
Total Assets | 43.31M | 42M | 38.98M | 61.56M | 82.78M |
- Stock Market
- Stocks
- FBRX Stock
- Financials Forte Biosciences
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
